Nasal Administration of Dexamethasone for Multiple Sclerosis (MS) Treatment

Phase 1WithdrawnNCT00674141

Hadassah Medical Organization10 enrolled

Overview

The study aims to assess the safety and efficacy of nasale administration of Dexamethasone in relapsing MS patients

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

MS Patient With Relpasing Remitting Attacks

Interventions

Dexamethasone soduim phosphateDRUG

nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * MS patients with esatblished relapsing remitting attacks * increase in EDSS of at least 1 point for a least one day Exclusion Criteria: * children under 18 * pregnant patients * patients with diabetes * known allergy to steroids * patients who received steroids within 3 months prior to the study

Locations (1)

Hadassah Medical Organization

Jerusalem, Israel

Outcomes

Primary Outcomes

reduction in the EDSS functional system score

Time frame: four months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.